Filing Flows › Neuroone Medical Technologies (NMTC) › Q2 FY25
Neuroone Medical Technologies (NMTC) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed May 13, 2025
Neuroone Medical Technologies (NMTC) reported revenue of $1.4M for the second quarter fiscal 2025 (Q2 FY25), +0.7% from a year earlier and -58% from the quarter before. Operating margin was -193.3%, net loss $2.3M (163.8% of revenue).
Neuroone Medical Technologies, Q2 FY25: revenue $1.4M (+0.7% year over year), operating margin -193.3%, net loss $2.3M, operating cash flow −$56K. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -58% | +0.7% |
| Operating profit | −$2.7M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | −$56K | — | — |
What changed
Revenue was $1.4M in Q2 FY25, up 1% year over year and down 58% from the previous quarter.
Gross margin was 55.6%, up 27.3 points from a year earlier. Operating costs exceeded revenue by $2.7M, an operating margin of -193.3%. Operating expenses grew 5% against revenue growth of 1%. The fastest-growing cost line was Research & development (+19%). The quarter ended with a net loss of $2.3M, after a profit of $1.8M the previous quarter.
Operating cash flow was −$56K. Non-cash charges added back $66K of depreciation and amortization and $250K of share-based compensation. Working capital and other items added $1.9M. Capital expenditures of $3K exceeded it, leaving free cash flow of −$59K.
Questions
What was Neuroone Medical Technologies' revenue in the second quarter fiscal 2025?
Neuroone Medical Technologies (NMTC) reported revenue of $1.4M for the second quarter fiscal 2025 (Q2 FY25), +0.7% from a year earlier and -58% from the quarter before.
Was Neuroone Medical Technologies profitable in the second quarter fiscal 2025?
Operating loss was $2.7M (-193.3% of revenue) and net loss $2.3M.